Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Strong results from the IMPACT study in low-A1c users.
The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?
LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...
People with type 2 diabetes should contact their physicians if they notice new pain, sores, or infections on their legs or feet.
JDRF and Helmsley Charitable Trust workshop highlights future goals and expectations for glucose-responsive insulin.
Making major improvements over current standard of care – how does this new treatment work? The FDA recently approved a new indication for a product that has been used...
How close is the UN to achieving its goal of “halting the rise in diabetes and obesity” by 2025?
New study shows that beta cell fragility may contribute to the risk of both type 1 and type 2 diabetes.
How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?
Views on FDA regulation, pipeline updates, and first vs. next-generation systems.
Type 1 diabetes has been prevented and cured in more than 500 ways in mice, but never in humans. nPOD researchers are trying to change that, one donated organ at a time.
TZD drug pioglitazone becomes second-ever diabetes drug to reduce heart disease and first to reduce strokes. Who might this benefit most?
By Christie Auyeung Last summer, the Diabetes Research Connection (DRC) officially launched a novel crowdfunding platform that directly connects donors with early-career...
Incredible presentation from CEO Derek Rapp on the state of the foundation. Plus, updates on the Bionic Pancreas and ViaCyte!
A new study from Dr. Doug Melton’s team provides hope for the future of stem cell treatment in diabetes. But there’s still a long way to go.
What are the projections for 2040?
When might this product reach the market?
A 38% decrease in cardiovascular death is exciting, but our work is nowhere near done.
Breaking news from Stockholm, Sweden, where our team is on the ground at the European Association for the Study of Diabetes (EASD) Conference – one of the largest...
Plus, an interview with Dr. Anne Peters on 23andMe and the future of individualized care.